Roivant Sciences Ltd. $ROIV Shares Purchased by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund boosted its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 96.6% during the 1st quarter, Holdings Channel.com reports. The firm owned 119,384 shares of the company’s stock after purchasing an additional 58,649 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Roivant Sciences were worth $3,307,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in ROIV. UBS Group AG boosted its stake in shares of Roivant Sciences by 570.0% during the 4th quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock valued at $399,080,000 after buying an additional 15,645,836 shares during the last quarter. Morgan Stanley raised its holdings in Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after acquiring an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after acquiring an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Roivant Sciences by 11,507.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after acquiring an additional 6,877,348 shares during the last quarter. Finally, Norges Bank bought a new position in Roivant Sciences during the 4th quarter valued at $112,750,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Stock Performance

Roivant Sciences stock opened at $34.51 on Monday. Roivant Sciences Ltd. has a 1 year low of $10.90 and a 1 year high of $37.00. The firm’s 50-day moving average is $31.68 and its 200-day moving average is $28.21. The company has a market cap of $24.82 billion, a P/E ratio of -57.52 and a beta of 1.11.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Citigroup lifted their price target on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Roivant Sciences in a report on Thursday, May 21st. Guggenheim upped their price objective on Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Finally, TD Cowen increased their target price on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.59.

Insiders Place Their Bets

In other news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at approximately $53,489,169.08. This represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 17,750 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the sale, the director owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,855,913 shares of company stock valued at $62,649,633 over the last quarter. Insiders own 10.80% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.